#radonc search results

Reirradiation (reRT) is reshaping cancer care—offering hope for recurrent tumors w/ advanced precision techniques like IMRT & SBRT. Multidisciplinary care, imaging, and innovation are key. #OpenAccess review by Andratschke et al: acsjournals.onlinelibrary.wiley.com/doi/full/10.33… @OncoAlert #RadOnc

CACancerJournal's tweet image. Reirradiation (reRT) is reshaping cancer care—offering hope for recurrent tumors w/ advanced precision techniques like IMRT & SBRT. Multidisciplinary care, imaging, and innovation are key. 

#OpenAccess review by Andratschke et al:
acsjournals.onlinelibrary.wiley.com/doi/full/10.33…

@OncoAlert #RadOnc

A few years ago, @rweichselbaum posed—ironically, but not entirely so—the question: what is the difference between radiotherapy and radiosurgery? In some ways, this review attempts to answer that very question. This table provides a synopsis of its contents. #radonc

CTuscanoMD's tweet image. A few years ago, @rweichselbaum posed—ironically, but not entirely so—the question: what is the difference between radiotherapy and radiosurgery?
In some ways, this review attempts to answer that very question.
This table provides a synopsis of its contents. #radonc…

One of our first-year residents, Dr. Rodriguez-Lopez, on why he chose @DukeCancer/@DukeMedSchool and what makes our #RadOnc residency great ⚡️

DukeRadOnc's tweet image. One of our first-year residents, Dr. Rodriguez-Lopez, on why he chose @DukeCancer/@DukeMedSchool and what makes our #RadOnc residency great ⚡️

📢 PACIFIC-2 is OUT: Simultaneous Durvalumab & Chemoradiation in Stage III NSCLC ⚠️A lot to learn from this (negative) trial in an unselected patient population⚠️ 🙏 for open access @OncoAlert #lcsm #radonc #immunotherapy #precisiononcology ascopubs.org/doi/10.1200/JC…


🔥 LUNAR trial: In oligometastatic hormone-sensitive #ProstateCancer, adding 2 cycles of 177Lu-PSMA 💥 ☢️ before SBRT ⬆️ doubled PFS (18 vs 7 mo, HR 0.32, p<0.001) with minimal added adverse events. 🚀 PSMA-RLT + SBRT = new frontier #ASTRO25 #RadOnc #NuclearMedicine @ASTRO_org

_ShankarSiva's tweet image. 🔥 LUNAR trial: In oligometastatic hormone-sensitive #ProstateCancer, adding 2 cycles of 177Lu-PSMA 💥 ☢️ before SBRT ⬆️ doubled PFS (18 vs 7 mo, HR 0.32, p&amp;lt;0.001) with minimal added adverse events. 
🚀 PSMA-RLT + SBRT = new frontier #ASTRO25 #RadOnc #NuclearMedicine @ASTRO_org
_ShankarSiva's tweet image. 🔥 LUNAR trial: In oligometastatic hormone-sensitive #ProstateCancer, adding 2 cycles of 177Lu-PSMA 💥 ☢️ before SBRT ⬆️ doubled PFS (18 vs 7 mo, HR 0.32, p&amp;lt;0.001) with minimal added adverse events. 
🚀 PSMA-RLT + SBRT = new frontier #ASTRO25 #RadOnc #NuclearMedicine @ASTRO_org
_ShankarSiva's tweet image. 🔥 LUNAR trial: In oligometastatic hormone-sensitive #ProstateCancer, adding 2 cycles of 177Lu-PSMA 💥 ☢️ before SBRT ⬆️ doubled PFS (18 vs 7 mo, HR 0.32, p&amp;lt;0.001) with minimal added adverse events. 
🚀 PSMA-RLT + SBRT = new frontier #ASTRO25 #RadOnc #NuclearMedicine @ASTRO_org

🧵1/4 PATH study(Cohort A) out in @IJROBP – Our trial asks whether undetectable post-operative HPV ctDNA can select OPC candidates for adj RT omission and found high rates of disease recurrence #radonc #hncsm redjournal.org/article/S0360-…

LChen_MD's tweet image. 🧵1/4 PATH study(Cohort A) out in @IJROBP – Our trial asks whether undetectable post-operative HPV ctDNA can select OPC candidates for adj RT omission and found high rates of disease recurrence #radonc #hncsm redjournal.org/article/S0360-…

Dr @jaydengracie on #priorAuthorization for #radonc #radiation cancer treatment. @ASTRO_org @ASCO #ASCOQLTY25 #priorAuth burden is rising over time, & this burden is felt WORSE in community practices. It wastes provider time, but more importantly it KILLS patients. #deathbyDelay

fumikochino's tweet image. Dr @jaydengracie on #priorAuthorization for #radonc #radiation cancer treatment. @ASTRO_org @ASCO #ASCOQLTY25 
#priorAuth burden is rising over time, &amp;amp; this burden is felt WORSE in community practices. It wastes provider time, but more importantly it KILLS patients. #deathbyDelay
fumikochino's tweet image. Dr @jaydengracie on #priorAuthorization for #radonc #radiation cancer treatment. @ASTRO_org @ASCO #ASCOQLTY25 
#priorAuth burden is rising over time, &amp;amp; this burden is felt WORSE in community practices. It wastes provider time, but more importantly it KILLS patients. #deathbyDelay
fumikochino's tweet image. Dr @jaydengracie on #priorAuthorization for #radonc #radiation cancer treatment. @ASTRO_org @ASCO #ASCOQLTY25 
#priorAuth burden is rising over time, &amp;amp; this burden is felt WORSE in community practices. It wastes provider time, but more importantly it KILLS patients. #deathbyDelay
fumikochino's tweet image. Dr @jaydengracie on #priorAuthorization for #radonc #radiation cancer treatment. @ASTRO_org @ASCO #ASCOQLTY25 
#priorAuth burden is rising over time, &amp;amp; this burden is felt WORSE in community practices. It wastes provider time, but more importantly it KILLS patients. #deathbyDelay

Great to have the chance to meet with the amazing #RadOnc residents @UofTDRO during their academic half day and then enjoy a fun lunch together @ldawsonmd

DKirschMDPhD's tweet image. Great to have the chance to meet with the amazing #RadOnc residents @UofTDRO during their academic half day and then enjoy a fun lunch together

@ldawsonmd

I had an amazing time returning to the old residency stomping grounds and seeing the new facility as visiting professor and BCM #radonc. Met a great group of residents and discussed optimization of #brachytherapy workflows!

AndrewFarach's tweet image. I had an amazing time returning to the old residency stomping grounds and seeing the new facility as visiting professor and BCM #radonc. Met a great group of residents and discussed optimization of #brachytherapy workflows!

A recently shared report detailed the past, present, and future of radiotherapy in cancer care. We spoke with Prof. Pat Price about the report. Read it here: hubs.li/Q03NmN5F0 #RadOnc #ASTRO25 #oncology

CancerNetwrk's tweet image. A recently shared report detailed the past, present, and future of radiotherapy in cancer care. We spoke with Prof. Pat Price about the report.

Read it here: hubs.li/Q03NmN5F0

#RadOnc #ASTRO25 #oncology

Fantastic mentee, @DrMcClellandLab member & @OUCollegeofMed MS4 Jared Gregston presenting his @ConquerCancerFd Merit Award-winning work on the rate & quality of #BreastCancer care following initial diagnosis at #ASCOQLTY25! #RadOnc #bcsm #RepresentationMatters #Match2026

TheDrWood's tweet image. Fantastic mentee, @DrMcClellandLab member &amp;amp; @OUCollegeofMed MS4 Jared Gregston presenting his @ConquerCancerFd Merit Award-winning work on the rate &amp;amp; quality of #BreastCancer care following initial diagnosis at #ASCOQLTY25!
#RadOnc
#bcsm
#RepresentationMatters
#Match2026
TheDrWood's tweet image. Fantastic mentee, @DrMcClellandLab member &amp;amp; @OUCollegeofMed MS4 Jared Gregston presenting his @ConquerCancerFd Merit Award-winning work on the rate &amp;amp; quality of #BreastCancer care following initial diagnosis at #ASCOQLTY25!
#RadOnc
#bcsm
#RepresentationMatters
#Match2026
TheDrWood's tweet image. Fantastic mentee, @DrMcClellandLab member &amp;amp; @OUCollegeofMed MS4 Jared Gregston presenting his @ConquerCancerFd Merit Award-winning work on the rate &amp;amp; quality of #BreastCancer care following initial diagnosis at #ASCOQLTY25!
#RadOnc
#bcsm
#RepresentationMatters
#Match2026

Truly an honor to be invited to Mt Sinai to speak, 9 years after finishing my residency @ken4englewood @MSROResidents #radonc #fullcircle

MKnoll_MD's tweet image. Truly an honor to be invited to Mt Sinai to speak, 9 years after finishing my residency 

@ken4englewood @MSROResidents

#radonc #fullcircle

Lab members Jared Gregston, Dr. @TheDrWood, & @MayaJanel in front of their #RadOnc #BreastCancer work at #ASCOQLTY25. Congrats to Jared on the Merit Award!

DrMcClellandLab's tweet image. Lab members Jared Gregston, Dr. @TheDrWood, &amp;amp; @MayaJanel in front of their #RadOnc #BreastCancer work at #ASCOQLTY25. 
Congrats to Jared on the Merit Award!
DrMcClellandLab's tweet image. Lab members Jared Gregston, Dr. @TheDrWood, &amp;amp; @MayaJanel in front of their #RadOnc #BreastCancer work at #ASCOQLTY25. 
Congrats to Jared on the Merit Award!

🙏 ⁦@BrianJDavisMDPh⁩ ⁦@MayoRadOnc⁩ for your 8 years of very dedicated service as ⁦@ABR_Radiology⁩ Board of Trustee for #radonc! Welcome ⁦@jmmrad⁩ ⁦@WashUMedRadOnc⁩ as the newest #radonc trustee! ⁦ ⁦@ASTRO_org

DrJohnSuh's tweet image. 🙏 ⁦@BrianJDavisMDPh⁩ ⁦@MayoRadOnc⁩ for your 8 years of very dedicated service as   ⁦@ABR_Radiology⁩ Board of Trustee for #radonc! Welcome ⁦@jmmrad⁩ ⁦@WashUMedRadOnc⁩ as the newest #radonc trustee! ⁦ ⁦@ASTRO_org⁩

Work outfit. Because even on cloudy rainy days you gotta bring patients your own sunshine ☀️😎🧬☢️. #RadOnc #gyncsm

IvyRadOncMD's tweet image. Work outfit. Because even on cloudy rainy days you gotta bring patients your own sunshine ☀️😎🧬☢️. #RadOnc #gyncsm

Artificial Intelligence: Aiding Precision and Practice in Radiation Oncology 🔗 ow.ly/Gh4c50X9svV #AI #RadOnc #RadiationOncology

Applied_RadOnc's tweet image. Artificial Intelligence: Aiding Precision and Practice in Radiation Oncology

🔗 ow.ly/Gh4c50X9svV

#AI #RadOnc #RadiationOncology

✨RadComp: First RCT of protons vs photons in breast #radiotherapy 🎀 At 6 mo, HRQOL (fatigue, body image, function) was excellent & similar in both arms ✅. 💨 FACIT - ⬆️satisfaction with protons 🚀 - not blinded though? #ASTRO25 #RadOnc @ASTRO_org @OncoAlert

_ShankarSiva's tweet image. ✨RadComp: First RCT of protons vs photons in breast #radiotherapy 🎀
At 6 mo, HRQOL  (fatigue, body image, function) was excellent &amp;amp; similar in both arms ✅.
💨 FACIT - ⬆️satisfaction with protons 🚀 - not blinded though?
 #ASTRO25 #RadOnc @ASTRO_org @OncoAlert
_ShankarSiva's tweet image. ✨RadComp: First RCT of protons vs photons in breast #radiotherapy 🎀
At 6 mo, HRQOL  (fatigue, body image, function) was excellent &amp;amp; similar in both arms ✅.
💨 FACIT - ⬆️satisfaction with protons 🚀 - not blinded though?
 #ASTRO25 #RadOnc @ASTRO_org @OncoAlert
_ShankarSiva's tweet image. ✨RadComp: First RCT of protons vs photons in breast #radiotherapy 🎀
At 6 mo, HRQOL  (fatigue, body image, function) was excellent &amp;amp; similar in both arms ✅.
💨 FACIT - ⬆️satisfaction with protons 🚀 - not blinded though?
 #ASTRO25 #RadOnc @ASTRO_org @OncoAlert
_ShankarSiva's tweet image. ✨RadComp: First RCT of protons vs photons in breast #radiotherapy 🎀
At 6 mo, HRQOL  (fatigue, body image, function) was excellent &amp;amp; similar in both arms ✅.
💨 FACIT - ⬆️satisfaction with protons 🚀 - not blinded though?
 #ASTRO25 #RadOnc @ASTRO_org @OncoAlert

Join @DukeCancer #RadOnc and author Stacy Wentworth, MD, and @DukeSci_Soc at @nightschoolbar on 10/24 for a talk on Dr. Bernie Fisher, the surgeon-scientist who revolutionized breast cancer treatment. Open to the public! 🔬 Learn more and RSVP: scienceandsociety.duke.edu/engage/events/…

DukeRadOnc's tweet image. Join @DukeCancer #RadOnc and author Stacy Wentworth, MD, and @DukeSci_Soc at @nightschoolbar on 10/24 for a talk on Dr. Bernie Fisher, the surgeon-scientist who revolutionized breast cancer treatment. Open to the public! 🔬

Learn more and RSVP: scienceandsociety.duke.edu/engage/events/…
DukeRadOnc's tweet image. Join @DukeCancer #RadOnc and author Stacy Wentworth, MD, and @DukeSci_Soc at @nightschoolbar on 10/24 for a talk on Dr. Bernie Fisher, the surgeon-scientist who revolutionized breast cancer treatment. Open to the public! 🔬

Learn more and RSVP: scienceandsociety.duke.edu/engage/events/…

EFECTO DEL TIEMPO (demoras e interrupciones en radioterapia. primera parte) youtu.be/qnyHyEPcTIo #RADBIOEDGE #RADONC

FREELANCEROG's tweet card. RADBIOEDGE4 1

youtube.com

YouTube

RADBIOEDGE4 1


A recently shared report detailed the past, present, and future of radiotherapy in cancer care. We spoke with Prof. Pat Price about the report. Read it here: hubs.li/Q03NmN5F0 #RadOnc #ASTRO25 #oncology

CancerNetwrk's tweet image. A recently shared report detailed the past, present, and future of radiotherapy in cancer care. We spoke with Prof. Pat Price about the report.

Read it here: hubs.li/Q03NmN5F0

#RadOnc #ASTRO25 #oncology

Does anyone remember the #radonc @ASTRO_org abstract (published in @IJROBP) from Europe about 20 years ago that showed low dose radiotherapy was a powerfully effective treatment for shingles

🧠DEMENTIA PREVENTION—Almost everyone needs to go out now and get the shingles vaccine ASAP. Don’t wait until age 50 for standard eligibility—ask your doctor for singles vax. MULTIPLE large studies worldwide now show that shingles vaccine strongly prevents dementia onset. Do it.

DrEricDing's tweet image. 🧠DEMENTIA PREVENTION—Almost everyone needs to go out now and get the shingles vaccine ASAP. Don’t wait until age 50 for standard eligibility—ask your doctor for singles vax. MULTIPLE large studies worldwide now show that shingles vaccine strongly prevents dementia onset. Do it.


One of our first-year residents, Dr. Rodriguez-Lopez, on why he chose @DukeCancer/@DukeMedSchool and what makes our #RadOnc residency great ⚡️

DukeRadOnc's tweet image. One of our first-year residents, Dr. Rodriguez-Lopez, on why he chose @DukeCancer/@DukeMedSchool and what makes our #RadOnc residency great ⚡️

📢 PACIFIC-2 is OUT: Simultaneous Durvalumab & Chemoradiation in Stage III NSCLC ⚠️A lot to learn from this (negative) trial in an unselected patient population⚠️ 🙏 for open access @OncoAlert #lcsm #radonc #immunotherapy #precisiononcology ascopubs.org/doi/10.1200/JC…


🎥Honorés de partager les réflexions pertinentes issues de notre conversation avec le Pr. Alfredo Conti (Université de Bologne) sur l'évolution du rôle de la radiochirurgie & l'importance de comprendre le parcours unique de chaque #patient. Voici son interview #EANS2025 #RadOnc


Always kind of surprised at this point when general medical knowledge works. Three recent patients w prostate cancer asking about “radiation side effects”: unstable angina, testicular torsion, and inguinal hernia. Some of those board questions were actually spot on! #radonc


9/n Bottom line: Lots of potential small sources of error. But we have the penumbra. And we debate the desired dose, in the first place! Most important thing is the outcomes are very good. Empiric patient outcomes are where #radonc shines! 👏


Pulsed low-dose rate chemoradiation reduces rates of severe esophagitis (26% vs 38% for historical controls) without compromising efficacy in patients with esophageal cancer & NSCLC From Joshua Meyer, MD @FoxChaseCancer #RadOnc #ASTRO25 ascopost.com/news/october-2…

ASCOPost's tweet image. Pulsed low-dose rate chemoradiation reduces rates of severe esophagitis (26% vs 38% for historical controls) without compromising efficacy in patients with esophageal cancer &amp;amp; NSCLC
From Joshua Meyer, MD @FoxChaseCancer

#RadOnc #ASTRO25
ascopost.com/news/october-2…

See how Vincent Bourbonne, MD, PhD, #RadOnc physician at Centre Hospitalier Universitaire de Brest, France, effectively handles the complexity of #Reirradiation cases with MIM Maestro™. ▶️ Watch the on-demand webinar now: bit.ly/4qqgh1R

mimsoftware's tweet image. See how Vincent Bourbonne, MD, PhD, #RadOnc physician at Centre Hospitalier Universitaire de Brest, France, effectively handles the complexity of #Reirradiation cases with MIM Maestro™.

▶️ Watch the on-demand webinar now: bit.ly/4qqgh1R

And this is the reason why it is so important to #connect in #collaborate. @RTOGFoundation @NRGonc offers an unparalleled platform to advanced Radiation Medicine frontiers! @StephenChunMD #RadOnc #MedOnc #SurgOnc @NSABPFoundation #Medicine

Our RTOGF Interns interviewed @StephenChunMD - Director of Radiation Oncology Clinical Research at MD Anderson Houston area locations and co-founder of the NRG Oncology Podcast - on his career & advice for early career investigators. Read more: ow.ly/PvaF50X7Ttn

RTOGFoundation's tweet image. Our RTOGF Interns interviewed @StephenChunMD - Director of Radiation Oncology Clinical Research at MD Anderson Houston area locations and co-founder of the NRG Oncology Podcast - on his career &amp;amp; advice for early career investigators. Read more: ow.ly/PvaF50X7Ttn


One month out from the 2025 @MDAndersonNews Boot Walk to #endcancer. Join the #radonc team and walk with us on Nov 15th at the TMC! I'm supporting The University of Texas MD Anderson Cancer Center! do.nr/7v2tj9t0 via @DonorDrive


The 10-year biochemical DFS rate was 86% with EBRT plus focal boost vs 71% with standard EBRT in those with intermediate- and high-risk prostate cancer. hubs.li/Q03N942N0 #pcsm #cancer #RadOnc


Ojo! en contextos clínicos localizados —como un hospital o área sanitaria concreta— ese “sobreajuste” puede ser funcional si el objetivo del modelo es optimizar decisiones dentro de esa misma población. #radonc #datascience #algorithms #DeepLearning #machinelearning

FREELANCEROG's tweet image. Ojo! 
en contextos clínicos localizados —como un hospital o área sanitaria concreta— ese “sobreajuste” puede ser funcional si el objetivo del modelo es optimizar decisiones dentro de esa misma población.
#radonc
#datascience #algorithms #DeepLearning #machinelearning

I love #radonc and radiosurgery because of the empiric outcomes. But we need to stop claiming <1 mm accuracy when our tech specs say the imaging has 2 mm resolution. Maybe can claim specifically <1 mm setup error…

A few years ago, @rweichselbaum posed—ironically, but not entirely so—the question: what is the difference between radiotherapy and radiosurgery? In some ways, this review attempts to answer that very question. This table provides a synopsis of its contents. #radonc

CTuscanoMD's tweet image. A few years ago, @rweichselbaum posed—ironically, but not entirely so—the question: what is the difference between radiotherapy and radiosurgery?
In some ways, this review attempts to answer that very question.
This table provides a synopsis of its contents. #radonc…


A few years ago, @rweichselbaum posed—ironically, but not entirely so—the question: what is the difference between radiotherapy and radiosurgery? In some ways, this review attempts to answer that very question. This table provides a synopsis of its contents. #radonc

CTuscanoMD's tweet image. A few years ago, @rweichselbaum posed—ironically, but not entirely so—the question: what is the difference between radiotherapy and radiosurgery?
In some ways, this review attempts to answer that very question.
This table provides a synopsis of its contents. #radonc…

We have theoretical physicists. Do we have theoretical radiation oncologists? #radonc #radmed @NehaVapiwala @HenningWillers @NiuSanford @sueyom @rweichselbaum @SameerKeoleMD @pipcosper @KimpleRandall


"When Disaster Strikes: Maintaining Cancer Care During Catastrophic Events" Proud of this panel @ASCO #ASCOQLTY25 including 3⃣ #radonc. Radiation care is a vital cancer treatment involving DAILY visits; disruptions during catastrophic events disproportionately effects our care.

fumikochino's tweet image. &quot;When Disaster Strikes: Maintaining Cancer Care During Catastrophic Events&quot; 

Proud of this panel @ASCO #ASCOQLTY25 including 3⃣ #radonc. Radiation care is a vital cancer treatment involving DAILY visits; disruptions during catastrophic events disproportionately effects our care.

🚨 NRGGU006: prospectively validated 🎯 PAM50 = predictive 🔬 biomarker for ARPI in #ProstateCancer! Adding apalutamide 💊 to salvage RT (no ADT) boosted 5-yr bPFS (72% vs 54%) & MFS (95% vs 82%) in luminal B tumors ➡️ no benefit in others. @DrSpratticus #ASTRO25 #RadOnc

_ShankarSiva's tweet image. 🚨 NRGGU006: prospectively validated 🎯 PAM50 = predictive 🔬 biomarker for ARPI in #ProstateCancer!

Adding apalutamide 💊 to salvage RT (no ADT) boosted 5-yr bPFS (72% vs 54%) &amp;amp; MFS (95% vs 82%) in luminal B tumors ➡️ no benefit in others. @DrSpratticus 
#ASTRO25 #RadOnc
_ShankarSiva's tweet image. 🚨 NRGGU006: prospectively validated 🎯 PAM50 = predictive 🔬 biomarker for ARPI in #ProstateCancer!

Adding apalutamide 💊 to salvage RT (no ADT) boosted 5-yr bPFS (72% vs 54%) &amp;amp; MFS (95% vs 82%) in luminal B tumors ➡️ no benefit in others. @DrSpratticus 
#ASTRO25 #RadOnc
_ShankarSiva's tweet image. 🚨 NRGGU006: prospectively validated 🎯 PAM50 = predictive 🔬 biomarker for ARPI in #ProstateCancer!

Adding apalutamide 💊 to salvage RT (no ADT) boosted 5-yr bPFS (72% vs 54%) &amp;amp; MFS (95% vs 82%) in luminal B tumors ➡️ no benefit in others. @DrSpratticus 
#ASTRO25 #RadOnc
_ShankarSiva's tweet image. 🚨 NRGGU006: prospectively validated 🎯 PAM50 = predictive 🔬 biomarker for ARPI in #ProstateCancer!

Adding apalutamide 💊 to salvage RT (no ADT) boosted 5-yr bPFS (72% vs 54%) &amp;amp; MFS (95% vs 82%) in luminal B tumors ➡️ no benefit in others. @DrSpratticus 
#ASTRO25 #RadOnc

Reirradiation (reRT) is reshaping cancer care—offering hope for recurrent tumors w/ advanced precision techniques like IMRT & SBRT. Multidisciplinary care, imaging, and innovation are key. #OpenAccess review by Andratschke et al: acsjournals.onlinelibrary.wiley.com/doi/full/10.33… @OncoAlert #RadOnc

CACancerJournal's tweet image. Reirradiation (reRT) is reshaping cancer care—offering hope for recurrent tumors w/ advanced precision techniques like IMRT &amp;amp; SBRT. Multidisciplinary care, imaging, and innovation are key. 

#OpenAccess review by Andratschke et al:
acsjournals.onlinelibrary.wiley.com/doi/full/10.33…

@OncoAlert #RadOnc

🔥 LUNAR trial: In oligometastatic hormone-sensitive #ProstateCancer, adding 2 cycles of 177Lu-PSMA 💥 ☢️ before SBRT ⬆️ doubled PFS (18 vs 7 mo, HR 0.32, p<0.001) with minimal added adverse events. 🚀 PSMA-RLT + SBRT = new frontier #ASTRO25 #RadOnc #NuclearMedicine @ASTRO_org

_ShankarSiva's tweet image. 🔥 LUNAR trial: In oligometastatic hormone-sensitive #ProstateCancer, adding 2 cycles of 177Lu-PSMA 💥 ☢️ before SBRT ⬆️ doubled PFS (18 vs 7 mo, HR 0.32, p&amp;lt;0.001) with minimal added adverse events. 
🚀 PSMA-RLT + SBRT = new frontier #ASTRO25 #RadOnc #NuclearMedicine @ASTRO_org
_ShankarSiva's tweet image. 🔥 LUNAR trial: In oligometastatic hormone-sensitive #ProstateCancer, adding 2 cycles of 177Lu-PSMA 💥 ☢️ before SBRT ⬆️ doubled PFS (18 vs 7 mo, HR 0.32, p&amp;lt;0.001) with minimal added adverse events. 
🚀 PSMA-RLT + SBRT = new frontier #ASTRO25 #RadOnc #NuclearMedicine @ASTRO_org
_ShankarSiva's tweet image. 🔥 LUNAR trial: In oligometastatic hormone-sensitive #ProstateCancer, adding 2 cycles of 177Lu-PSMA 💥 ☢️ before SBRT ⬆️ doubled PFS (18 vs 7 mo, HR 0.32, p&amp;lt;0.001) with minimal added adverse events. 
🚀 PSMA-RLT + SBRT = new frontier #ASTRO25 #RadOnc #NuclearMedicine @ASTRO_org

✨RadComp: First RCT of protons vs photons in breast #radiotherapy 🎀 At 6 mo, HRQOL (fatigue, body image, function) was excellent & similar in both arms ✅. 💨 FACIT - ⬆️satisfaction with protons 🚀 - not blinded though? #ASTRO25 #RadOnc @ASTRO_org @OncoAlert

_ShankarSiva's tweet image. ✨RadComp: First RCT of protons vs photons in breast #radiotherapy 🎀
At 6 mo, HRQOL  (fatigue, body image, function) was excellent &amp;amp; similar in both arms ✅.
💨 FACIT - ⬆️satisfaction with protons 🚀 - not blinded though?
 #ASTRO25 #RadOnc @ASTRO_org @OncoAlert
_ShankarSiva's tweet image. ✨RadComp: First RCT of protons vs photons in breast #radiotherapy 🎀
At 6 mo, HRQOL  (fatigue, body image, function) was excellent &amp;amp; similar in both arms ✅.
💨 FACIT - ⬆️satisfaction with protons 🚀 - not blinded though?
 #ASTRO25 #RadOnc @ASTRO_org @OncoAlert
_ShankarSiva's tweet image. ✨RadComp: First RCT of protons vs photons in breast #radiotherapy 🎀
At 6 mo, HRQOL  (fatigue, body image, function) was excellent &amp;amp; similar in both arms ✅.
💨 FACIT - ⬆️satisfaction with protons 🚀 - not blinded though?
 #ASTRO25 #RadOnc @ASTRO_org @OncoAlert
_ShankarSiva's tweet image. ✨RadComp: First RCT of protons vs photons in breast #radiotherapy 🎀
At 6 mo, HRQOL  (fatigue, body image, function) was excellent &amp;amp; similar in both arms ✅.
💨 FACIT - ⬆️satisfaction with protons 🚀 - not blinded though?
 #ASTRO25 #RadOnc @ASTRO_org @OncoAlert

We're excited to introduce our new 2025 Radiation Oncology Fellows at @UofTDRO! 📷Learn more about them: uoft.me/newfellow2025 @jenncroke #radonc #UofTDRO

UofTDRO's tweet image. We&apos;re excited to introduce our new 2025 Radiation Oncology Fellows at @UofTDRO! 📷Learn more about them: uoft.me/newfellow2025
@jenncroke #radonc #UofTDRO

#ASTRO25 has been wonderful to connect with the North American and international #radonc community…. 🙏🏽 for the memories! 😁

_ShankarSiva's tweet image. #ASTRO25 has been wonderful to connect with the North American and international #radonc community…. 🙏🏽 for the memories! 😁
_ShankarSiva's tweet image. #ASTRO25 has been wonderful to connect with the North American and international #radonc community…. 🙏🏽 for the memories! 😁
_ShankarSiva's tweet image. #ASTRO25 has been wonderful to connect with the North American and international #radonc community…. 🙏🏽 for the memories! 😁
_ShankarSiva's tweet image. #ASTRO25 has been wonderful to connect with the North American and international #radonc community…. 🙏🏽 for the memories! 😁

One of our first-year residents, Dr. Rodriguez-Lopez, on why he chose @DukeCancer/@DukeMedSchool and what makes our #RadOnc residency great ⚡️

DukeRadOnc's tweet image. One of our first-year residents, Dr. Rodriguez-Lopez, on why he chose @DukeCancer/@DukeMedSchool and what makes our #RadOnc residency great ⚡️

Truly an honor to be invited to Mt Sinai to speak, 9 years after finishing my residency @ken4englewood @MSROResidents #radonc #fullcircle

MKnoll_MD's tweet image. Truly an honor to be invited to Mt Sinai to speak, 9 years after finishing my residency 

@ken4englewood @MSROResidents

#radonc #fullcircle

A few years ago, @rweichselbaum posed—ironically, but not entirely so—the question: what is the difference between radiotherapy and radiosurgery? In some ways, this review attempts to answer that very question. This table provides a synopsis of its contents. #radonc

CTuscanoMD's tweet image. A few years ago, @rweichselbaum posed—ironically, but not entirely so—the question: what is the difference between radiotherapy and radiosurgery?
In some ways, this review attempts to answer that very question.
This table provides a synopsis of its contents. #radonc…

WOW! 🧠METIS trial (n=298) in #lungcancer brain mets: SRS ➕ TTFields ⚡vs SRS alone ✅ TTFields delays intracranial progression (HR 0.72, p=0.044) 📉12-mo progression: 47% vs 59%; ⬆️ with immunotherapy (HR 0.63) ❌No QoL / cognition decline; AEs mild skin #ASTRO25 #RadOnc

_ShankarSiva's tweet image. WOW! 🧠METIS trial (n=298) in #lungcancer brain mets: SRS ➕ TTFields ⚡vs SRS alone
✅ TTFields delays intracranial progression (HR 0.72, p=0.044)
 📉12-mo progression: 47% vs 59%; ⬆️ with immunotherapy  (HR 0.63)
 ❌No QoL / cognition decline; AEs mild skin
#ASTRO25 #RadOnc…
_ShankarSiva's tweet image. WOW! 🧠METIS trial (n=298) in #lungcancer brain mets: SRS ➕ TTFields ⚡vs SRS alone
✅ TTFields delays intracranial progression (HR 0.72, p=0.044)
 📉12-mo progression: 47% vs 59%; ⬆️ with immunotherapy  (HR 0.63)
 ❌No QoL / cognition decline; AEs mild skin
#ASTRO25 #RadOnc…
_ShankarSiva's tweet image. WOW! 🧠METIS trial (n=298) in #lungcancer brain mets: SRS ➕ TTFields ⚡vs SRS alone
✅ TTFields delays intracranial progression (HR 0.72, p=0.044)
 📉12-mo progression: 47% vs 59%; ⬆️ with immunotherapy  (HR 0.63)
 ❌No QoL / cognition decline; AEs mild skin
#ASTRO25 #RadOnc…
_ShankarSiva's tweet image. WOW! 🧠METIS trial (n=298) in #lungcancer brain mets: SRS ➕ TTFields ⚡vs SRS alone
✅ TTFields delays intracranial progression (HR 0.72, p=0.044)
 📉12-mo progression: 47% vs 59%; ⬆️ with immunotherapy  (HR 0.63)
 ❌No QoL / cognition decline; AEs mild skin
#ASTRO25 #RadOnc…

Hanging out with the ⁦@MDAndersonNews#radonc residents at the after party. #ASTRO25@PrajnanDasMD⁩ ⁦@ChelseaPinnix⁩ ⁦@yogagirldd

ACKoongMDPhD's tweet image. Hanging out with the ⁦@MDAndersonNews⁩ #radonc residents at the after party. #ASTRO25 ⁦@PrajnanDasMD⁩ ⁦@ChelseaPinnix⁩ ⁦@yogagirldd⁩

Great to have the chance to meet with the amazing #RadOnc residents @UofTDRO during their academic half day and then enjoy a fun lunch together @ldawsonmd

DKirschMDPhD's tweet image. Great to have the chance to meet with the amazing #RadOnc residents @UofTDRO during their academic half day and then enjoy a fun lunch together

@ldawsonmd

🚀 POPART trial (n=100): Post-op SABR (32.5 Gy/5fx) for BCR after prostatectomy ✅ well-tolerated; late ≥G2 GU 7.5%, GI 1% 📉 2-yr BRFS ~79% (PSA ↓ to 0.028 ng/mL) ➡️SBRT prostate bed salvage = promising, needs longer follow-up. #ASTRO25 #RadOnc @ASTRO_org

_ShankarSiva's tweet image. 🚀 POPART trial (n=100): Post-op SABR (32.5 Gy/5fx) for BCR after prostatectomy
✅ well-tolerated; late ≥G2 GU 7.5%, GI 1%
📉 2-yr BRFS ~79% (PSA ↓ to 0.028 ng/mL)
➡️SBRT prostate bed salvage = promising, needs longer follow-up. #ASTRO25 #RadOnc @ASTRO_org
_ShankarSiva's tweet image. 🚀 POPART trial (n=100): Post-op SABR (32.5 Gy/5fx) for BCR after prostatectomy
✅ well-tolerated; late ≥G2 GU 7.5%, GI 1%
📉 2-yr BRFS ~79% (PSA ↓ to 0.028 ng/mL)
➡️SBRT prostate bed salvage = promising, needs longer follow-up. #ASTRO25 #RadOnc @ASTRO_org
_ShankarSiva's tweet image. 🚀 POPART trial (n=100): Post-op SABR (32.5 Gy/5fx) for BCR after prostatectomy
✅ well-tolerated; late ≥G2 GU 7.5%, GI 1%
📉 2-yr BRFS ~79% (PSA ↓ to 0.028 ng/mL)
➡️SBRT prostate bed salvage = promising, needs longer follow-up. #ASTRO25 #RadOnc @ASTRO_org
_ShankarSiva's tweet image. 🚀 POPART trial (n=100): Post-op SABR (32.5 Gy/5fx) for BCR after prostatectomy
✅ well-tolerated; late ≥G2 GU 7.5%, GI 1%
📉 2-yr BRFS ~79% (PSA ↓ to 0.028 ng/mL)
➡️SBRT prostate bed salvage = promising, needs longer follow-up. #ASTRO25 #RadOnc @ASTRO_org

I had an amazing time returning to the old residency stomping grounds and seeing the new facility as visiting professor and BCM #radonc. Met a great group of residents and discussed optimization of #brachytherapy workflows!

AndrewFarach's tweet image. I had an amazing time returning to the old residency stomping grounds and seeing the new facility as visiting professor and BCM #radonc. Met a great group of residents and discussed optimization of #brachytherapy workflows!

My ❤️ always leaves happier after leaving @ASTRO_org conferences #ASTRO25 had many great things, but the best part was the people 👯‍♀️ 🙏🏻 you again to @ARRO_org for the Resident Educator of the year award! Looking forward to improving #radonc #meded throughout my career ☢️💪

StephDudzinski's tweet image. My ❤️ always leaves happier after leaving @ASTRO_org conferences 

#ASTRO25 had many great things, but the best part was the people 👯‍♀️

🙏🏻 you again to @ARRO_org for the Resident Educator of the year award! 

Looking forward to improving #radonc #meded throughout my career ☢️💪
StephDudzinski's tweet image. My ❤️ always leaves happier after leaving @ASTRO_org conferences 

#ASTRO25 had many great things, but the best part was the people 👯‍♀️

🙏🏻 you again to @ARRO_org for the Resident Educator of the year award! 

Looking forward to improving #radonc #meded throughout my career ☢️💪
StephDudzinski's tweet image. My ❤️ always leaves happier after leaving @ASTRO_org conferences 

#ASTRO25 had many great things, but the best part was the people 👯‍♀️

🙏🏻 you again to @ARRO_org for the Resident Educator of the year award! 

Looking forward to improving #radonc #meded throughout my career ☢️💪
StephDudzinski's tweet image. My ❤️ always leaves happier after leaving @ASTRO_org conferences 

#ASTRO25 had many great things, but the best part was the people 👯‍♀️

🙏🏻 you again to @ARRO_org for the Resident Educator of the year award! 

Looking forward to improving #radonc #meded throughout my career ☢️💪

So incredibly excited to share that I’m joining @ClevelandClinic as staff #RadOnc next year. 🌟 It’s been a fantastic training experience at @UW_RadoncDHO, though we’re happy to move back home. We made it, mom. 😊 @DrJohnSuh @CleClinicMD #ASTRO25

mustafabasree's tweet image. So incredibly excited to share that I’m joining @ClevelandClinic as staff #RadOnc next year. 🌟 

It’s been a fantastic training experience at @UW_RadoncDHO, though we’re happy to move back home.

We made it, mom. 😊

@DrJohnSuh @CleClinicMD #ASTRO25

That's a wrap! Another #ASTRO25 in the books. Great catching up with eveyrone. See you in Boston for #ASTRO26! #radonc #endcancer @MDAndersonNews

ACKoongMDPhD's tweet image. That&apos;s a wrap!  Another #ASTRO25 in the books.  Great catching up with eveyrone. See you in Boston for #ASTRO26! #radonc #endcancer @MDAndersonNews
ACKoongMDPhD's tweet image. That&apos;s a wrap!  Another #ASTRO25 in the books.  Great catching up with eveyrone. See you in Boston for #ASTRO26! #radonc #endcancer @MDAndersonNews
ACKoongMDPhD's tweet image. That&apos;s a wrap!  Another #ASTRO25 in the books.  Great catching up with eveyrone. See you in Boston for #ASTRO26! #radonc #endcancer @MDAndersonNews
ACKoongMDPhD's tweet image. That&apos;s a wrap!  Another #ASTRO25 in the books.  Great catching up with eveyrone. See you in Boston for #ASTRO26! #radonc #endcancer @MDAndersonNews

Work outfit. Because even on cloudy rainy days you gotta bring patients your own sunshine ☀️😎🧬☢️. #RadOnc #gyncsm

IvyRadOncMD's tweet image. Work outfit. Because even on cloudy rainy days you gotta bring patients your own sunshine ☀️😎🧬☢️. #RadOnc #gyncsm

Humbled & honored to join @ASTRO_org ’s Int’l Executive Committee for 2025-2026! This help shape global cancer care strategies, empower underserved & drive ASTRO’s mission. Thrilled to collaborate with leaders at #ASTRO2025! Grateful for the trust #RadOnc @KFSHRC @SARO_KSA

draldehaim's tweet image. Humbled &amp;amp; honored to join @ASTRO_org ’s Int’l Executive Committee for 2025-2026! 
This help shape global cancer care strategies, empower underserved &amp;amp; drive ASTRO’s mission. Thrilled to collaborate with leaders at #ASTRO2025!  

Grateful for the trust
#RadOnc
 @KFSHRC 
@SARO_KSA
draldehaim's tweet image. Humbled &amp;amp; honored to join @ASTRO_org ’s Int’l Executive Committee for 2025-2026! 
This help shape global cancer care strategies, empower underserved &amp;amp; drive ASTRO’s mission. Thrilled to collaborate with leaders at #ASTRO2025!  

Grateful for the trust
#RadOnc
 @KFSHRC 
@SARO_KSA

Loading...

Something went wrong.


Something went wrong.


United States Trends